Market Overview

PropThink: Lexicon's Stock Offering; In Biotech, it's "Raise When You Can"


By Jake King

Despite a stash of cash and liquid investments, Lexicon Pharmaceuticals (NASDAQ: LXRX) caught investors off guard two weeks ago by initiating a capital raise. The company had more than $225M in cash, equivalents, and short-term investments as of June 30 and burns approximately $25M quarterly, putting shareholders' minds at ease that LXRX was at least safe from the dilutive qualities of a stock offering. Unfortunately, the biotech rule of thumb is to raise when you can; Lexicon took advantage of share prices just short of their 52-week high and offered up roughly $40M in common stock. Shares have tumbled almost 20% since.

Lexicon's pipeline is lead by telotristat etiprate (LX1032), an oral tryptophan hydroxylase inhibitor in development as a treatment for carcinoid syndrome and ulcerative colitis. Carcinoid syndrome is a rare disorder - LX1032 has Orphan Drug and Fast-Track designation - that occurs when gastrointestinal tumors release large amounts of serotonin, causing diarrhea, bronchial restriction, abdominal pain, and flushing. LX1032 works by inhibiting tryptophan hydroxylase and subsequently reducing peripheral serotonin levels. Earlier this month, Lexicon initiated a Phase 3 study for patients with carcinoid syndrome who have become refractory to standard somatostatin analog therapies. Existing treatments include Novartis' (NYSE: NVS) Sandostatin (octreotide) and Ipsen's Somatuline® Depot (lanreotide), which is in a Phase 3 trial for carcinoid syndrome; both are injectable compounds. 

Analysts are concerned that generic octreotide may make LX1032 less substantive in the market. While Sandostatin's immediate release formulation is available generically, Sandostatin's long-acting formulation, injected once-monthly, is still exclusive, and prescribers usually move patients to the long-acting version as soon as tolerance is determined through the immediate release formulation. That formulation is injected 2 or 3 times daily, and the advantages of a long-acting or oral formulation are obvious. Sandostatin generated $1.44B in worldwide sales last year, suggesting that an equivalent oral drug stands to peel off a significant portion of the patient population, specifically those who become refractory to somatostatin therapies. 

Most analyst, however, are focused on Lexicon's second candidate, the dual SGLT1/SGLT2 inhibitor LX4211 for type-2 diabetes. Sodium-glucose co-transporter 1 (SGLT1) is the major intestinal glucose and galactose transporter, while SGLT2 is responsible for glucose reabsorption in the kidney. SGLT2 inhibition is commonly pursued for its ability to improve glucose excretion in urine, and adding the SGLT1 inhibitor may help stop or slow gastrointestinal reabsorption. Investors are well-aware of the opportunity for an effective SGLT1/SGLT2 inhibitor; LXRX set a new 52-week high just after releasing Phase 2b data in June, and the industry is pursuing the mechanism's opportunity as well. Johnson and Johnson (NYSE: JNJ) develops the SGLT2 inhibitor canagliflozin, Eli Lilly (NYSE: LLY) has empagliflozin, while AstraZeneca (NYSE: AZN) and Bristol-Myers Squibb (NYSE: BMY) co-develop dapagliflozin. The space is obviously crowding, but if LXRX can set itself apart with a dual inhibitor with improved safety and efficacy, it stands to benefit from the immense market for diabetes products. The company released Phase 2b data in June and expects to initiate a Phase 3 trial in the first half of 2013. Click Here Continue reading.

Read this article at PropThink.com.

About PropThink

PropThink is an intelligence service that delivers long and short trading ideas to investors in the healthcare and life sciences sectors. Our focus is on identifying and analyzing technically-complicated companies and equities that are grossly over or under-valued. We offer daily market coverage, weekly feature stories, and a newsletter to investors who subscribe on PropThink.com. To learn more, follow us on Twitter or visit us at http://www.propthink.com.

Disclaimer:

You should assume that as of the publication date of any report or letter, PropThink, LLC and persons or entities with whom it has relation ships (collectively referred to as "PropThink") has a position in all stocks (and/or options of the stock) covered herein that is consistent with the position set forth in our research report. Following publication of any report or letter, PropThink intends to continue transacting in the securities covered herein, and we may be long, short, or neutral at any time hereafter regardless of our initial recommendation. To the best of our knowledge and belief, all information contained herein is accurate and reliable, and has been obtained from public sources we believe to be accurate and reliable, and not from company insiders or persons who have a relationship with company insiders. PropThink was not compensated to publish this article. Our full disclaimer is available at http://www.propthink.com/disclaimer.







This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: PropThink via Thomson Reuters ONE

HUG#1653291

 

Around the Web, We're Loving...

Get Benzinga's Newsletters